Analyst
Equibles does not estimate personal net worth.
Dietmar Berger has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Gilead Sciences, Inc. on May 7, 2026. The companies whose calls Dietmar Berger spoke on are classified in the Healthcare sector.
“I'm pleased to share that the strong momentum across our research and clinical programs has accelerated since our full year earnings in February. This is supported by disciplined portfolio prioritization and strong execution.”
“And so Yes2Go every six months, of course, is a real benefit for people, and there's a lot of excitement, and we see that the launch is going well.”
“I'd like to start by reflecting on 2025 and thanking the research and development teams and partners for an exceptional year of clinical execution.”
“I mean, we're not, of course, commenting in depth on the regulatory strategy. But different factors give us confidence. One, we have additional data with regards to, you know, how is the medicine injected?”
Drug Manufacturers - General · Healthcare
